Antonio I.
- Country
- Sweden
- Department
- Avdelningen för hematologi
Research Overview
- Persistence of Remission Following Discontinuation of BCMA-CD3 Bispecific Antibodies in Multiple Myeloma Patients With Major M-Spike Response
- ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Data & Insights
Has run more than one trial at 4 of 90 partner sites.
Specializations
Multiple Myeloma Treatment
The investigator specializes in developing innovative therapeutic approaches for multiple myeloma, with particular emphasis on both newly diagnosed cases and treatment-resistant forms of the disease.
- First-line therapy optimization
- Post-transplant maintenance strategies
- Novel therapeutic combinations
Their research extends to evaluating novel immunotherapy agents and their integration into established treatment protocols.
Refractory Blood Cancers
Focus on advancing treatment options for patients with relapsed or refractory myeloma, particularly exploring combination therapies with innovative agents and established treatments.
- Multi-drug resistance management
- Alternative treatment pathways
- Targeted therapy approaches
The investigator examines various therapeutic combinations to overcome treatment resistance in advanced disease stages.
Pediatric and Young Adult Oncology
Dedicated to improving outcomes in acute lymphoblastic leukemia affecting young patients, from infants to young adults up to 45 years of age.
- Age-specific treatment protocols
- Immunotherapy applications
- Long-term survival strategies
Their work encompasses developing targeted interventions while considering quality of survival outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.